HHS Names Chief Economist, Regulatory Leader to Address Healthcare Affordability

Why It Matters

Mulligan’s economic expertise equips HHS to craft evidence‑based policies that could lower patient costs and reshape reimbursement models, influencing both providers and insurers.

Key Takeaways

• Casey Mulligan appointed HHS chief economist and regulatory officer
• Role focuses on tackling rising healthcare costs for Americans
• Mulligan brings experience from SBA and CEA under Trump
• Appointment aligns with Gallup poll showing healthcare top concern
• Could shape policy ahead of 2026 midterm elections

Pulse Analysis

Healthcare affordability has surged to the forefront of public opinion, with a March Gallup poll finding it as the top issue for U.S. adults. Policymakers are under pressure to demonstrate tangible solutions, especially as the 2026 midterm elections loom and voters scrutinize cost‑of‑care narratives. By installing a dedicated chief economist, HHS signals a commitment to data‑driven interventions that could influence everything from drug pricing to hospital reimbursement structures.

Casey Mulligan brings a rare blend of macro‑economic insight and regulatory experience. His tenure as chief counsel for advocacy at the Small Business Administration gave him a front‑row seat to the financial challenges faced by small firms, many of which cite health insurance premiums as a major expense. Earlier, as a chief economist on the Council of Economic Advisers, he helped shape national fiscal policy during the Trump administration, sharpening his ability to translate complex economic models into actionable policy. This background equips him to assess the systemic drivers of high medical costs and propose targeted reforms.

The strategic timing of Mulligan’s appointment suggests HHS will pursue more aggressive cost‑containment measures, potentially revisiting value‑based payment models, expanding price‑transparency mandates, and encouraging competition in high‑price markets like pharmaceuticals. Such moves could reverberate across the health‑care ecosystem, prompting insurers to redesign benefit structures and hospitals to accelerate efficiency initiatives. For industry stakeholders, Mulligan’s data‑centric approach offers both challenges and opportunities: aligning business models with emerging regulatory expectations could become a decisive factor in maintaining profitability while meeting the public’s demand for affordable care.